Dermatomyositis Therapeutics Pipeline Analysis 2018

CITY, Country, 2019-Jul-26 — /EPR Network/ —

Dermatomyositis is a rare inflammatory disease which can occur in any age. However, it is most common in children age group of 5 to 15 years, and people of late 40’s and early 60’s.

Download the sample report at:

Some of the most common symptoms observed in patients with dermatomyositis are erythema, inflammatory myopathy, myalgia, progressive muscle weakness, eyelid abnormality, and periorbital edema. The cause of the disease is still unknown; however, researchers and scientists have theorized that autoimmune reactions and viral infections can be accountable for the disease.

Get the detailed analysis at:

Some of the major companies involved in development of therapeutic agents for the treatment of dermatomyositis include Pfizer Inc., Neovacs S.A., Corbus Pharmaceuticals Holdings Inc., MedImmune LLC, and others. For instance, Pfizer Inc. is in the process of developing tofacitinib, as a Janus kinase inhibitor for the treatment of dermatomyositis.

Make enquiry before purchase at:


  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.


About Us:

Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455


Connect with us on: LinkedIn | Twitter | Facebook

Matched content

Editor’s pick

Do NOT follow this link or you will be banned from the site!